78 reports

  • GENETIC DISORDERS, COMMON SYMPTOMS OF GENETIC DISORDERS
  • GENETIC DISORDERS, PROGRESSION OF CF

Most genetic disorders are quite rare and affect one person in several thousand or even millions.

  • Genetic Disorder
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.

Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials Executive Summary Chapter ## – Introduction Chapter ## – Trends in Genetic Disorders dealmaking ##. ##.

  • Genetic Disorder
  • Pathology
  • World
  • Demand
  • Genetic diseases
  • Non-genetic diseases

The following are the commonly occurring monogenic disorders: Common types of genetic disorders Genetic diseases Global prenatal DNA sequencing market by genetic diseases - Market size and forecast 2017-2022 ($ mn) Down syndrome is one o

  • Genetic Disorder
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Natera, Inc.
  • JAPAN - CYSTIC FIBROSIS THERAPEUTICS MARKET (MILLION US$), 2014 - 2016
  • 6.2 CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET & FORECAST

Cystic fibrosis is a hereditary genetic disease afflicting about one in ## newborns in the US and Europe.

  • Genetic Disorder
  • World
  • Market Size
  • AbbVie Inc.
  • Editas Medicine, Inc.
  • GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022
  • 1.1 DEFINITION

Cystic fibrosis is a genetic disease.

  • Genetic Disorder
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • 1.1 DEFINITION
  • 5 Cystic Fibrosis Market, By Treatment Method

Cystic fibrosis is a genetic disease.

  • Genetic Disorder
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • II. Etiology and Genetics of Cystic Fibrosis
  • 1. CYSTIC FIBROSIS: DISEASE OVERVIEW

Etiology and Genetics of Cystic Fibrosis Cystic Fibrosis is a genetic disorder caused by having two mutated copies of the CFTR gene, each one copy from both parents. b.

  • Cystic Fibrosis
  • Genetic Disorder
  • World
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated

GENETIC FACTORS ARE ALSO A CONTRIBUTOR TO IPF; AROUND ## IN ## PEOPLE WITH IPF HAVE ANOTHER FAMILY MEMBER WITH THE DISEASE DUE TO A DISEASE CALLED FAMILIAL IDIOPATHIC FIBROSIS.

  • Genetic Disorder
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biologics, Inc.
  • PULMONARY HYPERTENSION

Engages in the development of drugs in areas such as immuno-oncology, oncology, immunoscience, virology, cardiovascular, fibrotic diseases, and metabolic and genetically defined diseases.

  • Genetic Disorder
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Canada
  • France
  • Italy
  • Forecast

(USA) ##.

  • Genetic Disorder
  • Medical Biotechnology
  • China
  • World
  • Market Shares
  • INTRODUCTION

IT IS AN AUTOSOMAL RECESSIVE GENETIC disorder caused by mutations in the CF gene.

  • Genetic Disorder
  • North America
  • United States
  • AstraZeneca PLC
  • Novartis AG

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Forest Laboratories, Inc.
  • Novartis AG
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • 7.3 GENETIC DISORDERS
  • VIRAL VECTOR MANUFACTURING MARKET FOR GENETIC DISORDERS, BY REGION, 2016-2023 (USD MILLION)

More than ## potential gene therapies for cancers, genetic disorders, and infectious diseases are currently under development.

  • Genetic Disorder
  • Pharmaceutical
  • North America
  • United States
  • Market Size
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF TURNER SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS
  • PROPORTION OF TURNER SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*

PROPORTION OF TURNER SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF TURNER SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* TURNER SYNDROME THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* In t

  • Genetic Disorder
  • Human Growth Hormone
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF BECKER MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF BECKER MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF BECKER MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF BECKER MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* IN TOTAL THERE WERE ## CLINICAL TRIALS CONDUCTED ON BECKER M

  • Genetic Disorder
  • Neurological Disorder
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* IN TOTAL THERE WERE ## CLINICAL TRIALS CONDUCTED ON

  • Antiviral
  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF TUBEROUS SCLEROSIS TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*
  • PROPORTION OF TUBEROUS SCLEROSIS TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*

TUBEROUS SCLEROSIS THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY TRIAL STATUS, 2018* CLINICAL TRIALS BY E## COUNTRIES: PROPORTION OF TUBEROUS SCLEROSIS TO GENETIC DISORDERS CLINICAL TRIALS Among the E## (Brazil, Russia, India, China, Mexico, Turkey and Indonesia) countries, China ha

  • Genetic Disorder
  • Neurological Disorder
  • World
  • Product Initiative
  • Novartis AG
  • PROPORTION OF SPINOCEREBELLAR ATAXIA (SCA) TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF SPINOCEREBELLAR ATAXIA (SCA) TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF SPINOCEREBELLAR ATAXIA (SCA) TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF SPINOCEREBELLAR ATAXIA (SCA) TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* IN TOTAL THERE WERE ## CLINICAL TRIALS CONDUCTED ON SP

  • Clinical Trial
  • Genetic Disorder
  • World
  • Product Initiative
  • Kissei Pharmaceutical Co., Ltd.
  • PROPORTION OF UREA CYCLE DISORDERS TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF UREA CYCLE DISORDERS TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF UREA CYCLE DISORDERS TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF UREA CYCLE DISORDERS TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* In total there were ## clinical trials conducted on Urea Cycle Disorde

  • Clinical Trial
  • Genetic Disorder
  • World
  • Product Initiative
  • Horizon Pharma plc
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF ADRENOLEUKODYSTROPHY (ADRENOMYELONEUROPATHY/ SCHILDER-ADDISON COMPLEX) TO GENETIC DISORDERS CLINICAL TRIALS
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF ADRENOLEUKODYSTROPHY (ADRENOMYELONEUROPATHY/ SCHILDER-ADDISON COMPLEX) TO GENETIC DISORDERS CLINICAL TRIALS

PROPORTION OF ADRENOLEUKODYSTROPHY (ADRENOMYELONEUROPATHY/ SCHILDER-ADDISON COMPLEX) TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF ADRENOLEUKODYSTROPHY (ADRENOMYELONEUROPATHY/ SCHILDER-ADDISON COMPLEX) TO GENETIC DISORDERS C

  • Clinical Trial
  • Dementia
  • Genetic Disorder
  • World
  • Product Initiative
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF SEVERE COMBINED IMMUNE DEFICIENCY (SCID) TO GENETIC DISORDERS CLINICAL TRIALS
  • PROPORTION OF SEVERE COMBINED IMMUNE DEFICIENCY (SCID) TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*

PROPORTION OF SEVERE COMBINED IMMUNE DEFICIENCY (SCID) TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF SEVERE COMBINED IMMUNE DEFICIENCY (SCID) TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* AS OF JULY 2018, THERE WERE ##

  • Cell Therapy
  • Genetic Disorder
  • Monoclonal Antibody
  • Therapy
  • GlaxoSmithKline plc
  • PROPORTION OF CHEDIAK-HIGASHI SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF CHEDIAK-HIGASHI SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF CHEDIAK-HIGASHI SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF CHEDIAK-HIGASHI SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* IN TOTAL THERE WERE ## CLINICAL TRIALS CONDUCTED ON CHEDIAK-HI

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Miltenyi Biotec GmbH
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF PRADER-WILLI SYNDROME (PWS) TO GENETIC DISORDERS CLINICAL TRIALS
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF PRADER-WILLI SYNDROME (PWS) TO GENETIC DISORDERS CLINICAL TRIALS

PROPORTION OF PRADER-WILLI SYNDROME (PWS) TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF PRADER-WILLI SYNDROME (PWS) TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF PRADER-WILLI SYNDROME (PWS) TO

  • Genetic Disorder
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF ALPHA-MANNOSIDOSIS TO GENETIC DISORDERS CLINICAL TRIALS
  • PROPORTION OF ALPHA-MANNOSIDOSIS TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF ALPHA-MANNOSIDOSIS TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF ALPHA-MANNOSIDOSIS TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* In total there were ## clinical trials conducted on Alpha-Mannosidosis, as

  • Clinical Trial
  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF CYSTINOSIS TO GENETIC DISORDERS CLINICAL TRIALS
  • PROPORTION OF CYSTINOSIS TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF CYSTINOSIS TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF CYSTINOSIS TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF CYSTINOSIS TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTR

  • Clinical Trial
  • Genetic Disorder
  • World
  • Product Initiative
  • Horizon Pharma plc
  • PROPORTION OF TAY-SACHS DISEASE TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF TAY-SACHS DISEASE TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF TAY-SACHS DISEASE TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF TAY-SACHS DISEASE TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* In total there were ## clinical trials conducted on Tay-Sa

  • Endocrine Disease
  • Genetic Disorder
  • Neurological Disorder
  • World
  • Nuo Therapeutics, Inc.
  • PROPORTION OF VON HIPPEL-LINDAU SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF VON HIPPEL-LINDAU SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS

PROPORTION OF VON HIPPEL-LINDAU SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF VON HIPPEL-LINDAU SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* IN TOTAL THERE WERE ## CLINICAL TRIALS CONDUCTED ON VON HI

  • Clinical Trial
  • Genetic Disorder
  • Medical Biotechnology
  • World
  • Product Initiative
  • PROPORTION OF OSTEOGENESIS IMPERFECTA TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF OSTEOGENESIS IMPERFECTA TO GENETIC DISORDERS CLINICAL TRIALS

PROPORTION OF OSTEOGENESIS IMPERFECTA TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF OSTEOGENESIS IMPERFECTA TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF OSTEOGENESIS IMPERFECTA TO GENETIC

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Mereo Biopharma Group Limited
  • PROPORTION OF NEUROFIBROMATOSES TYPE I (VON RECKLINGHAUSEN'S DISEASE) TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF NEUROFIBROMATOSES TYPE I (VON RECKLINGHAUSEN'S DISEASE) TO GENETIC DISORDERS CLINICAL TRIALS

PROPORTION OF NEUROFIBROMATOSES TYPE I (VON RECKLINGHAUSEN' S DISEASE) TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF NEUROFIBROMATOSES TYPE I (VON RECKLINGHAUSEN' S DISEASE) TO GENETIC DISORDERS CLINICAL TRIA

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • AstraZeneca PLC